Gastrointestinal symptoms in parkinson disease: Clinical aspects and management

Canadian Journal of Neurological Sciences

Volumn 38, Issue 4, 2011, Pages 557-564

  Salat Foix, D ^a   Andrews, C ^a   Meddings, J ^a   Suchowersky, O ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANALGESIC AGENT; ANTIPARKINSON AGENT; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLONAZEPAM; COLCHICINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; ISPAGULA; LAXATIVE; LEVODOPA; MACROGOL; MISOPROSTOL; MODAFINIL; OPIATE DERIVATIVE; PLACEBO; PRAMIPEXOLE; PROKINETIC AGENT; ROPINIROLE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; CLINICAL FEATURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DYSPEPSIA; DYSTONIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; VOMITING; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE;

ANTIPARKINSON AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PARKINSON DISEASE;

EID: 80053304291     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100012099     Document Type: Review

References (99)

1. Bower JH, Maraganore DM, McDonnell SK, RoccaWA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999 Apr 12;52(6):1214-20.
2. Benito-León J, Bermejo-Pareja F, Morales-González JM, et al. on behalf of the Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004 Mar 9;62(5):734-41.
3. Linder J, Stenlund H, Forsgren L. Incidence of PD and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010 Feb 15;25(3):341-8.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.
5. Muzerengi S, Contrafatto D, Chaudhuri KR. Non-motor symptoms: identification and management. Parkinsonism Relat Disord. 2007;13 Suppl 3:S450-6.
6. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003 Feb;2(2):107-16.
7. Natale G, Pasquali L, Ruggieri S, et al. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol Motil. 2008 Jul;20(7): 741-9.
8. Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci. 2010 Feb 15;289(1-2):69-73.
9. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005 Jun;20(6):726-33.
10. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010 Apr 30; 25(6):697-701.
11. Kyle G. The physical, social and emotional effects of bowel dysfunction in Parkinson's disease. Nurs Times. 2010 Aug 24-30;106(33):20-2.
12. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008 Jun 15;23(8):1065-75.
13. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of PD: refining the diagnostic criteria. Lancet Neurol. 2009 Dec;8(12):1150-7.
14. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic PD: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003 May;110(5):517-36.
15. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for PD-related brain pathology. Neurosci Lett. 2006 Mar 20;396(1):67-72.
16. Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of PD. Exp Neurol. 2009 Jul;218(1):154-61.
17. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces PD gastrointestinal neuropathology. Neurobiol Dis. 2009 Oct;36(1):96-102.
18. Blandini F, Balestra B, Levandis G, et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of PD. Neurosci Lett. 2009 Dec 31;467(3):203-7.
19. Kalf JG, de Swart BJ, Borm GF, et al. Prevalence and definition of drooling in PD: a systematic review. J Neurol. 2009 Sep;256(9): 1391-6. Epub 2009 Mar 14.
20. Kalf JG, Smit AM, Bloem BR, et al. Impact of drooling in PD. J Neurol. 2007 Sep;254(9):1227-32.
21. van der Burg JJ, Didden R, Jongerius PH, Rotteveel JJ. A descriptive analysis of studies on behavioural treatment of drooling (1970-2005). Dev Med Child Neurol. 2007 May;49(5): 390-4.
22. South AR, Somers SM, Jog MS. Gum chewing improves swallow frequency and latency in Parkinson patients: A preliminary study. Neurology. 2010;74;1198-202.
23. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010 Apr 13;74(15):1203-7.
24. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002 Nov;17(6):1318-20.
25. Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord. 2007 Nov 15;22(15):2268-73.
26. Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. Br J Clin Pharmacol. 2007 Jan;63(1):128-9.
27. Kushnir M. Eilam A. Heldman E. Modafinil reduces drooling in Parkinson's disease. Mov Disord 2006; 21 Suppl 13: S598-9.
28. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003 Nov 11;61(9):1279-81.
29. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004 Jan 13;62(1):37-40.
30. Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord. 2007 Dec;22(16):2430-5.
31. Meningaud JP, Pitak-Amnop P, Chikhani L, et al. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:48-57.
32. Miller N, Allcock L, Hildreth AJ, et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1047-9.
33. Plowman-Prine EK, Sapienza CM, OkunMS, et al. The relationship between quality of life and swallowing in PD. Mov Disord. 2009 Jul 15;24(9):1352-8.
34. González-Fernández J, Prieto-Albin R, Velasco-Palacios L, et al. Digestive disorders in Parkinson's disease: dysphagia and sialorrhea. Rev Neurol. 2010 Feb 8;50 Suppl 2:S51-4.
35. Castell JA, Johnston BT, Colcher A, et al. Manometric abnormalities of the oesophagus in patients with PD. Neurogastroenterol Motil. 2001 Aug;13(4):361-4.
36. Nagaya M, Kachi T, Yamada T, Igata A. Videofluorographic study of swallowing in PD. Dysphagia. 1998 Spring;13(2):95-100.
37. Ertekin C, Tarlaci S, Aydogdu I, et al. Electrophysiological evaluation of pharyngeal phase of swallowing in patients with PD. Mov Disord. 2002 Sep;17(5):942-9.
38. Schindler JS, Kelly JH. Swallowing disorders in the elderly. Laryngoscope. 2002 Apr;112(4):589-602.
39. Sung HY, Kim JS, Lee KS, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage PD. Mov Disord. 2010 Jul 28.
40. Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson's disease patients? J Clin Pharm Ther. 2009 Dec;34(6):673-6.
41. Baijens LW, Speyer R. Effects of therapy for dysphagia in PD: systematic review. Dysphagia. 2009 Mar;24(1):91-102.
42. Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med. 2002 Apr 11;346(15):1174-5.
43. Born LJ, Harned RH, Rikkers LF, et al. Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Mov Disord. 1996 Jan;11(1):53-8.
44. White GN, O'Rourke F, Ong BS, et al. Dysphagia: causes, assessment, treatment, and management. Geriatrics. 2008 May; 63(5):15-20.
45. Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in PD. Mov Disord. 1991;6(2):151-6.
46. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with PD. Mov Disord. 2001 Nov;16 (6):1041-7.
47. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006 Mar-Apr;29(2):61-7.
48. Nyholm D, Lennernäs H. Irregular gastrointestinal drug absorption in PD. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2): 193-203.
49. Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov Disord. 2010 Oct 15;25(13):2021-34.
50. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidencebased approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ. 2000 Jun 13;162(12 Suppl):S3-23.
51. Lertxundi U, Peral J, Mora O, et al. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm. 2008 Mar 1;65(5):414-9.
52. Friedenberg FK, Parkman HP. Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol. 2006 Jul;9(4):295-304.
53. Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord. 2008 Sep 15;23(12):1696-700.
54. Pierantozzi M, Pietroiusti A, Brusa L, at al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006 Jun 27;66(12):1824-9.
55. Lyte M. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori. Med Hypotheses. 2010 May;74(5):895-7.
56. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91.
57. Abbott RD, Ross GW, White LR, et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol. 2003 Oct;250 Suppl 3:III30-9.
58. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology. 2009 Nov 24;73(21):1752-8.
59. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007 Aug 15;22(11):1581-6.
60. Petrovitch H, Abbott RD, Ross GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009 Feb 15;24(3):371-6.
61. Kaye J, Gage H, Kimber A, et al. Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord. 2006 Aug;21(8): 1270-3.
62. Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand. 2008 Jan;117(1):60-4.
63. Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm. 2008;115 (3):443-60.
64. Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians-colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr. 1998 Aug 21; 110(15):535-7.
65. Shibata M, Morita Y, Shimizu T, et al. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci. 2009 Jan 15;276(1-2):79-83.
66. Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997 Nov;12(6):946-51.
67. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007 Jul 15;22(9): 1239-44.
68. Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.Mov Disord. 1997 Nov;12(6):952-7.
69. Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease. Mov Disord. 1997 May;12(3):423-5.
70. Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a longterm open label trial. Aliment Pharmacol Ther. 1997 Dec;11(6): 1059-66.
71. Chiu CM, Wang CP, Sung WH, et al. Functional magnetic stimulation in constipation associated with Parkinson's disease. J Rehabil Med. 2009 Nov;41(13):1085-9
72. Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and PD: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1503-7.
73. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov Disord. 2000 Jan; 15(1):71-6.
74. Merello M, Leiguarda R.Adynamic bowel syndrome in Parkinson's disease with dramatic response to apomorphine. Clin Neuropharmacol. 17(6):574-78.
75. Simón MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2009 Dec;34(4):273-7.
76. Rao SS, Valestin J, Brown CK, et al. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol. 2010 Apr;105(4):890-6.
77. Ron Y, Avni Y, Lukovetski A, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum. 2001 Dec; 44(12):1821-6.
78. FaridM, ElMonem HA, OmarW, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis. 2009 Jan;24 (1):115-20.
79. Krogh K, Christensen P. Neurogenic colorectal and pelvic floor dysfunction. Best Pract Res Clin Gastroenterol. 2009;23(4): 531-43.
80. Ford B. Pain in Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S98-103.
81. Norton C, Chelvanayagam S, Wilson-Barnett J, et al. Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology. 2003 Nov;125(5):1320-9.
82. Michelsen HB, Thompson-Fawcett M, Lundby L, et al. Six years of experience with sacral nerve stimulation for fecal incontinence. Dis Colon Rectum. 2010 Apr;53(4):414-21.
83. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of PD: meta-analysis of randomized controlled trials. Drug Saf. 2010 Feb 1;33(2):147-61.
84. Hauser RA, Panisset M, Abbruzzese G, et al on behalf of the FIRST-STEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early PD. Mov Disord. 2009 Mar 15;24(4):541-50.
85. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of PD. Clin Ther. 2007 Sep;29(9):1825-49.
86. No authors listed. Amantadine. In: McEvoy, G.K, editor. American Hospital Formulary Service-Drug Information 2005. Bethesda: American Society of Health-System Pharmacists; 2005. p. 592
87. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008 Nov 11;71(20):1634-8.
88. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008 Nov 11;71(20):1639-43.
89. Zesiewicz TA, Sullivan KL, Arnulf I, et al on behalf of the Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Mar 16;74(11):924-31.
90. HorstinkM, Tolosa E, Bonuccelli U, et al on behalf of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDSES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-202.
91. Goetz CG, Tilley BC, Shaftman SR, et al on behalf of the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70.
92. Chaudhuri KR, Martinez-Martin P, SchapiraAH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006 Jul;21(7):916-23.
93. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. 2007 Oct 15;22(13):1901-11.
94. Visser M, Marinus J, StiggelboutAM, Van Hilten JJ.Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord. 2004 Nov;19(11):1306-12.
95. Perez Lloret S, Pirán Arce G, Rossi M, et al. Validation of a new scale for the evaluation of sialorrhea in patients with PD. Mov Disord. 2007 Jan;22(1):107-11.
96. McHorney CA, Bricker DE, Kramer AE, et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development. Dysphagia. 2000 Summer;15(3):115-21.
97. McHorney CA, Bricker DE, Robbins J, et al. The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling. Dysphagia. 2000 Summer;15 (3):122-33.
98. McHorney CA, Robbins J, Lomax K, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia. 2002 Spring;17(2):97-114.
99. Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996 Jun;39(6):681-5.